** Shares of drug developer Replimune Group REPL.O fall 76.5% to $2.90 premarket
** Co says the U.S. FDA declined to approve its experimental skin cancer drug, called RP1, for patients with advanced melanoma
** The FDA, in its so-called complete response letter, said the clinical trial to test the drug "was not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness"
** FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population - REPL
** Co plans to urgently interact with the FDA to find a path forward
** Co was testing RP1 in combination with Bristol Myers Squibb's BMY.N Opdivo in patients with advanced skin cancer
** Up to last close, REPL up 1.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.